# NCT06305754 (NCT06305754)

> Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

No report yet. It can be ordered.

- Drugs tested: sacituzumab tirumotecan
- Indication: EGFR-mutated advanced nonsquamous non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06305754
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-small Cell Lung Cancer (NSCLC)
- Interventions: Sacituzumab tirumotecan; Pemetrexed; Carboplatin; H1 Receptor Antagonist; H2 Receptor Antagonist; Acetaminophen (or equivalent); Dexamethasone (or equivalent); Steroid Mouthwash (dexamethasone or equivalent)
- Enrollment: 550
- Primary outcome: Overall Survival (OS)

## Indexed commentary on NCT06305754 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06305754
